Urinary Tract Infection Therapeutics Market Introduction and Overview
According to SPER Market Research, the Global Urinary Tract Infection Therapeutics Market is estimated to reach USD 12.13 Billion by 2033 with a CAGR of 3.1%.
The report includes an in-depth analysis of the Global Urinary Tract Infection Therapeutics Market, including market size and trends, product mix, applications, and supplier analysis. Infections that affect any component of the urinary system, such as the kidneys, bladder, ureters, and urethra, are referred to as urinary tract infections. Bacteria that enter the urinary tract through the urethra are the main cause of these illnesses. Symptoms of urinary tract infections (UTIs) include burning or pain when urinating, murky or bloody urine, and urgency. In order to avoid consequences and recurrent infections, prompt diagnosis and adequate treatment are essential.
- October 2021: The US Food and Drug Administration (FDA) received a new drug application (NDA) from Spero Therapeutics Inc. requesting clearance for tebipenem HBr tablets to treat complicated UTIs (cUTIs), including pyelonephritis, brought on by susceptible microorganisms.
- September 2021: Biapenem was introduced by BDR Pharma, a top generic pharmaceutical company in India, to treat patients with urinary tract infections, lower respiratory infections, and intra-abdominal infections.
Market Opportunities and Challenges
A greater emphasis on the creation of innovative medications is anticipated to offer substantial expansion opportunities for participants in the worldwide market for the treatment of urinary tract infections. It is anticipated that increased R&D will also offer profitable expansion opportunities for companies operating in the urinary tract infection treatment industry. Complicated UTIs are predicted to become more common during the projection period as a result of rising UTI recurrence rates, rising bacterial resistance in UTI patients, and overuse of antibiotics. The need for novel urinary tract infection treatments (drugs) is therefore anticipated to rise globally as a result, and this pattern is anticipated to persist throughout the projected period, propelling the market's expansion. Additionally, rising consumer awareness of the link between diabetes and obesity and bladder dysfunction, a greater emphasis on the creation of novel treatments, and the quick adoption of cutting-edge technologies for UTI treatment are some of the major trends propelling the market for urinary tract infection treatments as a whole.
The development of the worldwide urine tract infection treatment market is anticipated to be hampered by side effects related to the use of UTI medications. For example, the expansion of the urinary tract infection therapeutic market over the projected period may be hindered by side effects associated with UTI therapeutics like fluoroquinolones, such as fluctuations in blood sugar levels and central nervous system disorders like insomnia, seizures, and anxiety. The development of the worldwide market for treatments for urinary tract infections is also predicted to be hampered by a lack of awareness among people in developing and impoverished nations.
Market Competitive Landscape
The global market for treatments for urinary tract infections is very competitive, with a number of major companies present. To increase their market presence, these businesses concentrate on tactics including alliances, product launches, and mergers and acquisitions. The major key players in the Global Urinary Tract Infection Therapeutics Market are: Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Drug, By Indication
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others.
|
COVID-19 Impact on Global Urinary Tract Infection Therapeutics Market
The market for treatments for urinary tract infections has been significantly impacted by the COVID-19 pandemic, as has the whole global healthcare sector. The market dynamics have been impacted by shifts in patient behaviour, disruptions in supply chains, and the reallocation of healthcare resources towards pandemic management. On the other hand, the long-term management of UTIs is probably going to benefit from the increased emphasis on infection prevention and cleanliness practices.
Key Target Audience:
- Pharmaceutical Companies
- Healthcare Providers
- Research and Development Teams
- Patients and Caregivers
- Health Insurance Providers
- Government Health Departments
- Pharmacy and Retail Chains
- Others
Our in-depth analysis of the Urinary Tract Infection Therapeutics Market includes the following segments:
|
By Drug
|
Aminoglycoside Antibodies
Azoles and Amphotericin B
Cephalosporin
Nitrofurans
Penicillin and Combinations
|
|
By Indication
|
Complicated UTI
Neurogenic Bladder Infection
Recurring Complicated UTI
Uncomplicated UTI
Other Indications
|
|
By Region:
|
Asia-Pacific
Europe
Middle East & Africa
North America
Latin America
|
Key Topics Covered in the Report:
- Global Urinary Tract Infection Therapeutics Market Size (FY’2023-FY’2033)
- Overview of Global Urinary Tract Infection Therapeutics Market
- Segmentation of Global Urinary Tract Infection Therapeutics Market By Drug (Aminoglycoside Antibodies, Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones, Sulphonamides, Tetracycline, Other Drugs)
- Segmentation of Global Urinary Tract Infection Therapeutics Market By Indication (Complicated UTI, Neurogenic Bladder Infection, Recurring Complicated UTI, Uncomplicated UTI, Other Indications)
- Statistical Snap of Global Urinary Tract Infection Therapeutics Market
- Expansion Analysis of Global Urinary Tract Infection Therapeutics Market
- Problems and Obstacles in Global Urinary Tract Infection Therapeutics Market
- Competitive Landscape in the Global Urinary Tract Infection Therapeutics Market
- Impact of COVID-19 and Demonetization on Global Urinary Tract Infection Therapeutics Market
- Details on Current Investment in Global Urinary Tract Infection Therapeutics Market
- Competitive Analysis of Global Urinary Tract Infection Therapeutics Market
- Prominent Players in the Global Urinary Tract Infection Therapeutics Market
- SWOT Analysis of Global Urinary Tract Infection Therapeutics Market
- Global Urinary Tract Infection Therapeutics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Urinary Tract Infection Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Urinary Tract Infection Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Urinary Tract Infection Therapeutics Market
7. Global Urinary Tract Infection Therapeutics Market, By Drug (USD Million)
7.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Drug, 2023-2033
7.2. Aminoglycoside Antibodies
7.3. Azoles and Amphotericin B
7.4. Cephalosporin
7.5. Nitrofurans
7.6. Penicillin and Combinations
7.7. Quinolones
7.8. Sulphonamides
7.9. Tetracycline
7.10. Other Drugs
8. Global Urinary Tract Infection Therapeutics Market, By Indication (USD Million)
8.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Indication, 2023-2033
8.2. Complicated UTI
8.3. Neurogenic Bladder Infection
8.4. Recurring Complicated UTI
8.5. Uncomplicated UTI
8.6. Other Indications
9. Global Urinary Tract Infection Therapeutics Market Forecast, 2019-2033 (USD Million)
9.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share
10. Global Urinary Tract Infection Therapeutics Market, By Drug, 2019-2033 (USD Million)
10.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2019-2026)
10.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2027-2033)
11. Global Urinary Tract Infection Therapeutics Market, By Indication, 2019-2033 (USD Million)
11.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2019-2026)
11.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2027-2033)
12. Global Urinary Tract Infection Therapeutics Market, By Region, 2019-2033 (USD Million)
12.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2019-2026)
12.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2027-2033)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Rest of Middle East & Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America
13. Company Profile
13.1. Almirall SA
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. AstraZeneca
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Bayer AG
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Bristol-Myers Squibb Company
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Cipla Inc.
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Dr. Reddys Laboratories Ltd
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. GlaxoSmithKline PLC
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Merck & Co. Inc
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Novartis AG
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Pfizer
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Shionogi & Co. Ltd.
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
